Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Ipilimumab, nivolumab & brentuximab vedotin for R/R Hodgkin lymphoma

Stephen Ansell • 21 Dec 2018
ASH 2018
Hodgkin Lymphoma Lymphoma Brentuximab vedotin Checkpoint inhibitors Ipilimumab Nivolumab
E4412

Relapsed/refractory Hodgkin lymphoma (R/R HL) continues to pose a significant clinical challenge. Here, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, presents the preliminary safety and response data from the Phase I/II E4412 trial (NCT01896999) investigating ipilimumab and nivolumab when given together with brentuximab vedotin for the treatment of R/R HL. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals